


**Product Name** : Linifanib  
**Cat. No.** : PC-45859  
**CAS No.** : 796967-16-3  
**Molecular Formula** : C<sub>21</sub>H<sub>18</sub>N<sub>5</sub>O  
**Molecular Weight** : 375.3989  
**Target** : VEGFR  
**Solubility** : 10 mM in DMSO

1. Dai Y, et al. *J Med Chem*. 2007 Apr 5;50(7):1584-97.
2. Shankar DB, et al. *Blood*. 2007 Apr 15;109(8):3400-8.
3. Albert DH, et al. *Mol Cancer Ther*. 2006 Apr;5(4):995-1006.
4. Pierotti CL, et al. *Biochem J*. 2023 Apr 28;BCJ20230035.



## Biological Activity

Linifanib (ABT-869) is a potent multi-RTKs inhibitor of members of **VEGFR** and **PDGFR** families with IC<sub>50</sub> of 4/3/3/14/4/66/190/170 nM for KDR/FLT1/CSF1R/KIT/FLT3/PDGFRβ/FLT4/Tie2, respectively. Linifanib (ABT-869) shows much less active (IC<sub>50</sub>>10 μM) against other nonrelated tyrosine kinases, such as steroid receptor coactivator and EGFR. Linifanib (ABT-869) inhibits RTK phosphorylation (IC<sub>50</sub>=2, 4, and 7 nM for PDGFRβ, KDR, and CSF-1R, respectively) and VEGF-stimulated proliferation (IC<sub>50</sub>=0.2 nM for human endothelial cells). Linifanib (ABT-869) exhibits efficacy in human fibrosarcoma and breast, colon, and small cell lung carcinoma xenograft models (ED<sub>50</sub>=1.5-5 mg/kg, twice daily). Linifanib (ABT-869) also is a small molecule inhibitor of necroptosis by targeting RIPK1 kinase

## References

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com